Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on February 14, 2022, covering events that occurred on February 11, 2022. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "JAGX".
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or total debt levels. The report focuses exclusively on a specific capital transaction.
Material Changes
On February 11, 2022, the Company executed a privately negotiated exchange agreement with a holder of royalty interest. Key details of this transaction include:
- Shares Issued: 2,375,000 shares of common stock.
- Consideration: A reduction of $1,733,750 in the outstanding balance of the royalty interest held by the counterparty.
- Regulatory Basis: The issuance relied on the exemption from registration provided under Section 3(a)(9) of the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, or specific risks associated with the transaction beyond the standard regulatory disclosure. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the impact of the 2,375,000 new shares on total outstanding share count and potential dilution.
- Confirm the remaining balance of the royalty interest obligation following the $1,733,750 reduction.
- Review the full text of the Exchange Agreement (referenced as Exhibit 10.6 in the 2019 10-Q) for any covenants or future obligations.